FOLD

Amicus Therapeutics is a commercial-stage rare disease biotech company with two marketed small molecule therapies: Galafold, an oral precision medicine approved in over 40 countries for Fabry disease in patients with amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment approved in the U.S., European Union, United Kingdom, Canada, Australia, Switzerland, and Japan for late-onset Pompe disease. The company is also expanding into other rare disease indications through an exclusive U.S. commercialization agreement for DMX-200, a Phase 3 small molecule candidate for focal segmental glomerulosclerosis and other conditions.

Pipeline

Catalyst Calendar